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1. Introduction 
Hyperthyroidism is the consequence of excessive thyroid hormone action (AACE Thyroid 
Guidelines, 2002). In many cases, it results from excessive activity of the thyroid gland, with 
a  pathologically increased production of thyroid hormones. The causes of hyperthyroidism 
include several conditions, that are listed in Table 1. 
 
 Toxic diffuse goiter (Graves’ disease) 
 Toxic adenoma 
 Toxic multinodular goiter (Plummer’s disease) 
 Painful subacute thyroiditis 
 Silent thyroiditis, including lymphocytic and postpartum variations 
 Iodine-induced hyperthyroidism (for example, related to amiodarone therapy) 
 Excessive pituitary TSH or trophoblastic disease 
 Excessive ingestion of thyroid hormone 
Table 1. Causes of hyperthyroidism (AACE Thyroid Guidelines,2002) 
Graves’ disease is the most common cause of hyperthyroidism. It is an autoimmune 
disorder, caused by the presence of autoantibodies directed against the thyroid-stimulating 
hormone (TSH) receptor (TRAb), chronically stimulating thyroid hormone synthesis and 
secretion, and resulting in an excessive amount of triiodothyronine (T3) and thyroxine (T4) 
and  gland growth. In iodine sufficient areas, this prototypical autoimmune disease is the 
most common cause of thyrotoxicosis in young women as well as in children and 
adolescents, and it is characterized by thyrotoxicosis, goitre and typical manifestations such 
as ophthalmopathy and pretibial myxedema.  
According to the American Association of Clinical Endocrinologists guidelines (AACE, 
2002), the diagnosis of hyperthyroidism relates on TSH values. Thus, with the exception of 
the excess of TSH secretion, hyperthyroidism of any cases results in a lower-than-normal or 
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suppressed TSH level, together with an increase of free T4 and  free T3 in the case of overt 
disease.  
Once hyperthyroidism has been diagnosed, three main therapeutic options are available, 
including radioactive iodine, surgical intervention (thyroidectomy) and anti-thyroid drug. 
In US, radioactive iodine is currently the treatment of choice for adults with Graves’ 
disease, except for pregnant or breast-feeding women, because of its adverse effects on 
fetal gland and its appearance in the breast milk. Overall, radioactive iodine is a safe and 
effective therapy, that can be either administered through an ablative or with a smaller 
doses regimen in order to render the patient euthyroid. In any case, hypothyroidism 
requiring a lifelong thyroid replacement therapy is an inevitable consequence with 
radioiodine therapy.  
Thyroidectomy was frequently used in the past, but its use is now limited to pregnant 
women intolerant to antithyroid drugs, or to patients refusing radioactive iodine as a 
definitive treatment. Possible complications associated with surgical treatment of Graves’ 
disease include laryngeal nerve damage and vocal cord paralysis, hypoparathyroidism and 
hypothyroidism. 
Anti-thyroid drug treatment is still a widely used approach in the treatment of 
hyperthyroidism. Since the 1940s, thionamides have been used as anti-thyroid drugs in the 
management of Grave’s disease (Laurberg et al., 2006). This class of drugs includes 
propylthiouracil (PTU), benzylthiouracil, carbimazole and methimazole (MMI), and all of 
them have been shown to have comparable efficacy in inducing hyperthyroidism remission 
(Cooper, 2005). 
All these compounds act through the inhibition of thyroid peroxidase, the enzyme 
responsible for the synthesis of thyroid hormones, thus leading to a reduced hormone 
secretion (Laurberg et al., 2006). Recently, an alternate mechanism of action has been 
proposed, relating their efficacy in patients with Graves’ disease to a direct 
immunosuppressive effect (Laurberg et al., 2006). 
Despite the similar efficacy, the choice of the anti-thyroid drug is conditioned by other drug 
characteristics and/or by their pharmacokinetics profile. For instance, MMI has a longer 
half-life than PTU, and thanks to its once-a-day administration, it represents the best choice 
when addressing patients compliance. On the other hand, PTU is the drug of choice for 
treating pregnant  and breast-feeding women, because of its limited transfer into the 
placenta and breast milk (Streetman et al., 2003). PTU is often preferred to MMI also for the 
additional property of inhibiting the peripheral conversion of T4 to T3. 
Although widely used, anti-thyroid drugs have been reported to be associated with a wide 
range of adverse effects, such as skin eruptions, liver dysfunction and agranulocytosis;  
fever, arthralgias and arthritis are other common clinical manifestation, usually occurring 
within the first few months of administration. 
The occurrence of these side-effects can be influenced by several factors, such as drug 
starting dose or treatment duration (Nakamura et al., 2003). 
In addition, over the past 2 decades, several cases of thionamides-associated autoimmune 
vasculitis have been reported, with variable clinical presentation and severity.  
Vasculitis are a heterogeneous group of inflammatory disorders of the blood vessels, that 
occur as a part of several autoimmune disorders. In many cases they are largely mediated by 
the deposition of immune complexes that  precipitate and become trapped within vessel 
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walls, stimulating an immune response that ultimately leads to vascular injury. This 
mechanism usually occurs in secondary vasculitis, frequently associated with infections or 
systemic autoimmune diseases, whereas in the primary vasculitis, immune deposits are 
generally absent (Kallenberg & Heeringa, 1998). 
Clinical manifestations of vasculitis largely depend on the type of vessels and the specific 
disctrict involved, resulting in a wide-range of signs and symptoms. 
The Chapel Hill Consensus Conference nomenclature is one of the most widely used to 
distinguish different forms of vasculitis, based on vessel size (large, medium, and small), as 
shown in Table 2 (Jennette & Falk, 2007). 
 
Large Vessel Vasculitis 
 Giant Cell Arteritis 
 Takayasu Arteritis 
Medium-Sized Vessel Vasculitis 
 Polyarteritis Nodosa 
 Kawasaki Disease  
Small Vessel Vasculitis 
 Wegener’s Granulomatosis 
 Churg-Strauss Syndrome 
 Microscopic Polyangiitis 
 Henoch-Schönlein Purpura 
 Cryoglobulinemic Vasculitis 
 Cutaneous leukocytoclastic angiitis 
Table 2. Classification of vasculitis according to the Chapel Hill Consensus Conference 
2. Thionamides-related vasculitis in autoimmune thyroid disorders 
2.1 Autoimmune markers of thionamides-related vasculitis 
Overall, vasculitis have been mainly reported in patients treated with PTU, and most of 
PTU-induced vasculitis are associated with an increase of anti-neutrophil cytoplasmic 
antibody (ANCA) circulating levels.  
ANCA are antibodies directed against myeloid lysosomal enzymes, that can be identified by 
indirect immunofluorescence (IIF) with human neutrophils. These autoantibodies can have 
a cytoplasmic (cANCA) or a perinuclear (pANCA) distribution pattern, that can be detected 
by ELISA (Savige et al., 2000). In particular, cANCA are directed against antiproteinase3 
(PR3-ANCA), and they are specific for Wegener’s granulomatosis (Van der Wonde et al., 
1985), whereas pANCA can be directed against several antigens, the most important being 
myeloperoxidase (MPO-ANCA). pANCA is a serological marker for microscopic 
polyangiitis, but it can also be detected in patients with systemic lupus erythematosus, 
rheumatoid arthritis and drug-induced vasculitis (Jennette & Falk, 1997).  
Any of these patterns can occur in patients with drug-induced ANCA-positive vasculitis 
and atypical ANCA against several antigens, like elastase, azurocin, cathepsine G, 
lactoferrin and lyzozim have been also reported. 
Although the pathogenetic role of these autoantibodies in drug-induced vasculitis has not 
been fully elucidated yet, several hypotheses have been proposed.     
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Thus, it has been reported that PTU can selectively accumulate into neutrophils where it 
can bind to myeloperoxidase, changing or inactivating the heme structure of the enzyme 
(Lee et al., 1988). It has been suggested that, in susceptible individuals, the enzyme altered 
by PTU could then stimulate the production of anti-myeloperoxidase antibodies, inducing 
neutrophils degranulation and vascular damage (D’Cruz et al., 1995). In particular, MPO-
ANCA seems to play an important role in the development of tissue damage in vasculitis 
or glomerulonephritis (Ashizawa et al., 2003; Arimura et al., 1993). It has also been 
suggested that viral infections could trigger the development of the autoimmune chain 
reaction.  
Overall, ANCA autoantibodies are frequently detected in patients with Graves’ disease 
treated with anti-thyroid drugs, regardless of the presence of clinical manifestations of 
vasculitis. 
Anti-thyroid drugs ANCA-associated vasculitis occurs more frequently in women, 
consistently with the fact that Graves’ disease is more common in female gender.  
It has been reported that the prevalence of MPO-ANCA is higher in patients treated with 
PTU than in those treated with MMI (Wada et al., 2002).  
Thus, the prevalence of ANCA positivity has been estimated to average 26% of PTU-treated 
subjects (Gunton et al., 2000), being even higher in treated children (Hirokazu et al., 2000).  
In a study of 117 patients with Graves’ disease, Sera et al. reported that MPO-ANCA was 
negative in all patients treated with MMI as well as in untreated patients, whereas it was 
detected in 37.5% of patients receiving PTU (Sera et al., 2000). Furthermore, the proportion 
of patients positive for MPO-ANCA increased with the prolongation of PTU treatment (Sera 
et al., 2000).  
In a retrospective study of 61 patients with Graves’ disease, Wada et al. reported that 25% of 
patients treated with PTU showed positive MPO-ANCA, unlike 3.4%  of patients receiving 
MMI. Moreover, the sole patient MPO-ANCA positive treated with MMI had been taking 
PTU for six years before starting MMI treatment (Wada et al., 2002). 
The annual incidence of MPO-ANCA-associated vasculitis in patients treated with anti-
thyroid drugs has been estimated to be between 0.53 and 0.79 patients per 10,000, although 
several mild cases may not have been reported (Noh et al., 2009).  
However, not all ANCA positive patients develop the clinical manifestations of vasculitis, 
and several factors such as type of drug, ethnicity, timing and dose, treatment duration may 
concur to the development of overt clinical manifestations. 
Overall, the incidence of ANCA positive vasculitis is higher with PTU, being estimated to be  
39.2 times the incidence reported with MMI (Noh et al., 2009). 
As for ethnicity, the prevalence of ANCA positivity seems to be similar in different ethnical 
groups, although Gunton et al. suggested that ANCA-positive vasculitis may be more 
common in patients of Asian origin, being nearly half of the reported cases of PTU-induced 
ANCA-associated vasculitis from Japan (Gunton et al., 1999). 
The timing and doses of thionamides reported in ANCA-associated vasculitis have also 
been variable. In fact, even if long-term treatment with anti-thyroid drugs seems to have a 
stronger association with the risk of vasculitis, these complications can also occur within few 
months after starting the treatment. Furthermore, ANCA-associated vasculitis have  
been also reported in patients treated with low doses of both MMI and PTU (Noh et al., 
2009). 
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Moreover, it seems that drug dose and duration of anti-thyroid treatment use, together with 
the titers of antibodies could be related with the clinical course of ANCA-associated 
vasculitis. Thus, Morita et al. (Morita et al., 2000) reported that anti-thyroid drug-induced 
ANCA-associated vasculitis was more frequent in patients resistant to drug treatment, who 
were receiving high doses over a prolonged period of time and with high titers of MPO-
ANCA; furthermore, clinical manifestations disappeared according to decreasing values of 
antibodies. This finding suggests that high titer of MPO-ANCA may be necessary to induce 
vasculitis. 
Beside the role of thionamides in inducing the formation of specific autoantibodies, an 
alternate hypothesis has to be taken into account. 
Thus, given the common autoimmune background, a possible association of ANCA-
positivity with the autoimmune disease itself has been suggested.  
This hypothesis has been tested in a prospective study, where a group of patients with 
newly diagnosed Graves’ disease were followed up before and during therapy with PTU, 
and compared to a cross-sectional group of previously diagnosed Graves’ patients who had 
already been treated with PTU, of patients with Hashimoto thyroiditis and those with toxic 
nodular goiter, as well as to healthy controls. As a result, all untreated newly diagnosed 
Graves’ patients were ANCA negative, but 32.1% became ANCA positive after initiating 
PTU administration. On the other hand, patients with Hashimoto disease, untreated toxic 
nodular goiter and euthyroid subjects did not show ANCA positivity. This study suggested 
that it is PTU treatment, and not hyperthyroidism or autoimmunity, which induces ANCA 
production (Ozduman Cin et al., 2009). In agreement with this, ANCA prevalence is 
increased in Graves’ disease, but not in patients with other autoimmune thyroid disease, 
such as Hashimoto thyroiditis (Harper et al., 2004). Furthermore, it has also been 
demonstrated that PTU administration is associated with ANCA positivity at a similar rate 
in both patient with Graves’ disease and those with toxic multinodular goiter, suggesting 
that PTU but not Graves’ disease itself is the most important factor for ANCA development 
(Yazisiz et al., 2008). 
2.2 Clinical manifestations of thionamides-related vasculitis 
Clinical presentation and severity of anti-thyroid drug-induced vasculitis are variable, and 
largely related to the type of vessels and to the anatomical district involved. 
Thus, although not all ANCA positive patients develop a clinical disease, a wide-range of 
clinical symptoms have been reported in patients with thionamides-related vasculitis. 
ANCA-associated vasculitis is usually characterized by small vessel inflammation and 
necrosis, that may involve any system and organ, being arthralgia and fever the most 
commonly reported clinical manifestations (Morita et al., 2000). 
An ANCA-positive vasculitis in association with anti-thyroid drugs was first reported in 
1992 by Stankus and Johnson, who described a patient treated with PTU who developed 
respiratory failure and MPO-ANCA positive test (Stankus & Johnson, 1992).  
Since then, several cases of ANCA-associated vasculitis in patients with Graves’ disease 
treated with anti-thyroid drugs have been described, although ANCA-positive vasculitis 
have also been reported in patients with toxic multi-nodular goiter treated with PTU. Thus,  
in 1999 a case report of a PTU-induced vasculitis was described in an elderly women with 
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toxic multi-nodular goiter, presenting with haemoptysis and acute renal failure (Gunton et 
al., 1999). 
Overall, drug-induced vasculitis presenting symptoms may include renal involvement 
(67%), arthralgia (48%), fever (37%), skin manifestations (30%), respiratory tract involvement 
(27%), myalgia (22%), scleritis (15%) as well as other manifestations (18%) (Gunton et al., 
1999). 
As for skin manifestations, leukocytoclastic vasculitis, principally affecting the lower limbs, 
is the most common cutaneous manifestation (Gunton et al., 1999; Day et al., 2003).  
In addition, several cases of pulmonary involvement have been reported, including 
pulmonary infiltrates associated with respiratory failure, eosinophilic pleuritis, interstitial 
pneumonitis or respiratory distress syndrome and pulmonary harmorrhage (Stankus & 
Johnson, 1992; Chevrolet et al., 1991).  
Renal involvement in drug-induced vasculitis is also common. In 1995, D’Cruz et al. 
published the first report of renal biopsy-proven vasculitis in two patients treated with anti-
thyroid drugs. Both patients developed a crescentic glomerulonephritis and responded to 
immunosuppressive therapy and dismission of anti-thyroid drugs (D’Cruz et al., 1995).  
Recently, Chen YX et al. published a retrospective study of 19 patients with ANCA-positive 
vasculitis associated with PTU treatment. In this study, renal injury was the most common 
manifestation, occurring in 94.74% of cases. At renal biopsy, focal proliferative 
glomerulonephritis and necrotizing glomerulonephritis with crescent formation, minor 
glomerular abnormalities, IgA nephropathy, membranous nephropathy, focal proliferative 
glomerulonephritis, granulomatous interstitial nephritis and focal segmental glomerular 
sclerosis were all described (Chen YX et al., 2007).  
Rare fatalities have been also reported in patients with anti-thyroid drugs-associated 
vasculitis. Batchelor et al. described the case of a 60-year-old man with a history of Graves' 
disease, treated with PTU, and presenting with rash, pancytopenia, and lymphadenopathy 
and subsequently developing acute renal failure and diffuse alveolar hemorrhage, who died 
despite the discontinuation of PTU and an aggressive therapy including 
immunosuppressive drugs and plasmapheresis (Batchelor & Holley, 2006). 
Thus, even if in the majority of cases vasculitis usually resolve after the discontinuation of 
anti-thyroid drugs, patients can present with more severe or life-threatening manifestations. 
In a study evaluating cutaneous and systemic manifestations following thionamides 
administration, death occurred in 10% of all published cases, with a predominance in 
patients with involvement of multiple organ systems (ten Holder et al., 2002). 
Until 2005, the main case reports of thionamides induced-vasculitis described above all 
renal, musculoskeletal and cutaneous manifestations. In that period, the first case of 
thionamides-induced central nervous system (CNS) vasculitis has been also reported (Vanek 
et al., 2005): a PTU-treated patients presenting with generalized muscle spasms, amnesia 
and confusion,  who showed a complete resolution of CNS symptoms after cessation of drug 
administration.   
Since most of thionamides-related vasculitis have been associated with PTU, MMI treatment 
has been advocated as safer for the treatment of Graves’ disease; however, several cases of 
vasculitis following MMI administration have been reported. 
In 1995, Kawaki et al. reported the first case of ANCA-associated vasculitis caused by MMI: 
a 24-year-old woman with Graves' disease treated with MMI for 4 years, who developed 
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recalcitrant ulcers on the lower legs and ANCA positivity, improved after MMI was 
withdrawn (Kawaki et al., 1995). 
Besides skin manifestations, also renal involvement, such as crescentic glomerulonephritis 
(D’Cruz et al., 1995), and pulmonary involvement, with hemoptysis and hypoxic respiratory 
failure (Tsai et al., 2001) have been reported in MMI-treated patients. 
Furthermore, we recently reported the first case of MMI induced CNS vasculitis in a young 
woman with Graves’ disease, completely recovered after the discontinuation of treatment 
(Tripodi et al., 2008). CNS vasculitis was suspected on the basis of the clinical features and 
neurological examination, and confirmed by brain magnetic resonance imaging (RMN) and 
single-photon emission computed tomography (SPECT). In our patient, ANCA test was 
negative, supporting the concept that ANCA are not critical for the development of drug-
induced vasculitis. 
Thus, although less common than with PTU, vasculitis associated with other thionamides-
drugs  therapy have been also described.  
Although more infrequently, carbimazole-associated vasculitis have been reported. 
Carbimazole has been associated with leukocytoclastic vasculitis and acute renal failure 
secondary to interstitial nephritis, without any evidence of ANCA positivity (Day et al., 
2003), and to ANCA-positive vasculitis with crescentic glomerulonephritis (D’Cruz et al., 
1995). Respiratory involvement in carbimazole-treated patients appears to be less common, 
although a case of MPO-ANCA vasculitis with massive pulmonary hemorrhage and 
necrotizing glomerulonephritis has been described (Calanas-Continente et al., 2005). Also a 
case of polyneuropathy, with evidence of microvasculitis in nerve biopsy, was reported as 
associated to this drug administration (Leger et al., 1984). 
In a large cross-sectional study of 407 patients with Graves’ disease, Harper et al. reported 
that both PTU and carbimazole therapy were associated with an increases rate of ANCA-
positivity, although the risk in carbimazole-treated patients was smaller than in PTU-treated 
ones (15.9% and 33.3% respectively vs 4,6% of controls) (Harper et al., 2004). Its 
administration has also been related to the development of rare side effects, such as those 
described by Sève et al., who reported the first case of eosinophilic granulomatous vasculitis 
localized to the stomach in a patient with Graves’ disease treated for five months with 
carbimazole, with complete resolution of clinical manifestations after drug dismission (Sève 
et al., 2005). 
Since there are no evidence that carbimazole can accumulate in neutrophils or to act as a 
hapten as PTU, the underlying mechanism associated to the development of vasculitis 
related with other thionamides-drugs has not been yet elucidated. 
2.3 Anti-thyroid-induced ANCA-associated vasculitis and idiophatic ANCA vasculitis: 
Comparison of clinical manifestations and outcomes 
Clinical and serological characteristics of drug-induced and idiophatic systemic vasculitis 
are similar; however, the appropriate diagnosis is of great importance since they may have a 
different treatment and prognosis. 
Thus, the removal of anti-thyroid drugs is usually associated with the resolution of the 
clinical symptoms of vasculitis, whereas patients with idiophatic vasculitis always need to 
be treated more aggressively with immunosuppressive and anti-inflammatory drugs, or 
plasmapheresis.  
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Clinical and serological data from idiophatic and anti-thyroid drug-induced ANCA positive 
vasculitis were compared in a 11-year retrospective study. In this cohort (Bonaci-Nikolic et 
al., 2005), both groups of patients showed a similar high frequency of arthralgia and 
myalgia, whereas skin involvement, especially represented by urticaria and  
urticaria-like vasculitis, was more common in patients treated with anti-thyroid drugs, with 
histological evidence of leucocytoclastic vasculitis. Furthermore, patients with  
idiophatic systemic vasculitis showed more frequently fever, weight loss, renal and 
respiratory manifestations, pulmonary-renal syndrome, ear/nose and nervous system 
manifestations.  
As for serological profile, patients with drug-induced vasculitis, showed positivity for 
ANAs and antihistone antibodies, and had high levels of IgM anticardiolipin antibodies 
cryoglobulinemia and low C4 values (Wiik et al., 2005; Bonaci-Nikolic et al., 2005).  
Hence, drug-induced vasculitis seem to have a milder course and a better long-term 
prognosis, since the withdrawal of anti-thyroid drugs usually leads to the resolution of 
clinical manifestations in the vast majority of cases. 
Thus, the prognosis of anti-thyroid-induced ANCA-associated vasculitis is usually good as 
long as the drug is discontinued. However, early recognition of clinical symptoms is very 
important because of the potential risk of life-threatening injury, such as pulmonary-renal 
syndrome, with pulmonary hemorrhage and renal failure. In these patients, additional 
treatment with steroids and/or immunosuppressive agents should be recommended.   
In a retrospective study of fifteen patients with PTU-induced ANCA-associated vasculitis, 
Gao et al. investigated treatment protocols and outcomes of patients, suggesting that 
immunosuppressive therapy should be administrated only in those patients with vital organ 
involvement, such as lung and kidney vasculitis, in order to prevent progression to 
irreversible disease.  
Interestingly, unlike what is normally found in patients with primary ANCA-associated 
vasculitis (Hogan et al., 2005), none of the patients with drug-induced vasculitis experienced 
relapse after the discontinuation of immunosuppressive therapy at follow-up (Gao et 
al.,2008). 
Moreover, immunosuppressive therapy may be administered only for a shorter period of 
time, usually 6-12 months, than in primary ANCA-associated vasculitis, without any further 
maintenance therapy (Gao et al., 2008). 
3. Conclusion 
Anti-thyroid drugs are a common and widespread treatment for Graves’ disease and the 
other forms of hyperthyroidism. It is a safe and efficacy treatment, and it is the treatment of 
choice in patients refusing radioactive iodine as definitive treatment or during pregnancy 
and breast-feeding.  
However, this treatment has been associated with several side effects and among them, 
vasculitis, with a wide-range of severity and clinical presentations. 
Vasculitis are more commonly reported in PTU-treated patients, with a long duration of 
treatment, and with positivity for ANCA autoantibodies. 
Thionamides-related vasculitis usually recover after discontinuation of therapy, although 
rare cases of fatalities have been also reported. 
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